Blueprint Medicines (BPMC) 30 Oct 242024 Q3 Earnings call transcript

Company Profile

Participants

Jenna Cohen	executive
Kathryn Haviland	executive
Philina Lee	executive
Christina Rossi	executive
Michael Landsittel	executive
Marc Frahm	analyst
Fouad Namouni	executive
Bradley Canino	analyst
Reni Benjamin	analyst
Paul Jeng	analyst
Tommie Reerink	analyst
Derek Archila	analyst
Michael Ulz	analyst
Ami Fadia	analyst
Peter Lawson	analyst
Laura Prendergast	analyst
David Lebowitz	analyst
Sudan Loganathan	analyst

Call transcript

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Nadia, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines Third Quarter 2024 Financial Results Conference Call. [Operator Instructions]. Thank you. begin may you Cohen, your conference. Jenna

Jenna Cohen

which Nadia. Medicines Third you, Call. today. morning, press Good to we Operating morning, Blueprint to This release, a issued welcome and we the Quarter discuss Conference topics plan everyone, Results Thank outlines XXXX and Financial

we'll Investors access can section website www.blueprintmedicines.com. that of release today by as the as our You reviewing well going press slides the be to the at

Chief are Kate President, Commercial Haviland, Chief Officer; Philina Chief Officer; Landsittel, Chief Rossi, is Research also Namouni, today Executive Officer; on and Lee, Financial Christy the me Q&A. Operating Development, Fouad Mike and line Joining Officer; during available and

outlined I'd described SEC. a cause the to the materially, our are and during of on Before you that differ including and those as in risks reports may with today like are our subject Slide statements we number uncertainties, X to made actual some of the these call filed to begin, statements results remind forward-looking

are Blueprint disclaims place You and I'll to such update over Kate. forward-looking obligation now any on statements. these to cautioned undue the any statements, call reliance to hand not

Kathryn Haviland

momentum results has we million between the course $XXX of for morning, you, to another confidence our product and us raise quarter Thank will in trajectory million year expectations estimate morning, given Adding drive year. long-term AYVAKIT to of to us in this and the $XXX revenue. AYVAKIT significantly And year-to-date additional revenue we revenue end creation good This sales over and we beyond. our impressive providing now XXXX the that strong a growth. foundation reported Jenna, everyone. and strong value shareholder

of billion be successful $X.X Placing first full revenue date. on to ISM launches $X opportunity firmly rare realizing positioning than the its among billion our on peak in the in launch ISM disease run rate a to to path launch. and AYVAKIT's are more AYVAKIT We year most

This a demonstrate demonstrated and clinical easy ISM. drives medicine, treatment clinically to AYVAKIT symptom we deep sustained diseases that a transforms and build patients significantly so have must paradigms to Blueprint, impact need. with differentiated for say meaningful To impact and we that blockbuster is medical simple and At high do. meaningful, not with

Now the a Treatment and lives transforming safety ISM with pioneer in treatment over their several and of patients the years well-tolerated with is reclaim consistent ISM. study, paradigm AYVAKIT control profile. in to allowing is

years. harder continued for have recent advanced have as long-term become as blockbuster across Blueprint, therapeutic durable in market believe strengthened With a be It years generation setting ISM legislative never access the on challenging AYVAKIT leader data the all been up been and these successfully come. we regulatory market macro indolent to headwinds Building adoption, saturated has both environment easy. backdrop of become spectrum through managed of only strong have to and has has a what commercial is areas and the we of all At challenges. brand

all medicines to specific range we short-term dynamics are the the that asset to the as including a Our face, tremendous medical rare have dynamics disease navigating market. done unique commercial of the launches teams intrinsic quarterly as markets job dynamics and are dynamics face, and the well industry-wide and

Leveraging other growth on in our And cell year-over-year. talk will results burden a for in patients always While we dynamics, treatment and these $X efficacy, mast with results we building our shortly. long-term maintained the to full cell our opportunity. account of the We on expertise medical of inflammatory and urticaria peak designed managing into experience. billion bar foundation impact have detail thousands our in about wild-type raise short-term taking broaden the revenue KIT to addressing tolerability all our are can biology, BLU-XXX and a patient compelling continue in leadership offer. significant associated ISM by By needs delivering working mediated AYVAKIT when than we deep the conviction focused commercial more mast more administration. inhibitor. with BLU-XXX, be for diseases to chronic Philina

We for an to across will markets. BLU-XXX our to further later populations on large have on command made progress expanding see update the call. the by growth opportunity established share significant in markets is those of a treated and twofold: we the Christy drive portfolio the provide

significant our on report to long-term our revenue burn position value in this ramp a while growth and compelling we with opportunities, realize creation. QX AYVAKIT's decline in in coupled strong maintaining most As results our a disciplined investment cash year, us today, product focus places our

Mike We in financial now turn on it detail. will future. results more portfolio early performance we more quarter's foundation talk look later in to solid reviewing will a financial XXXX. our are to call, our Blueprint's this the forward for to I priorities discuss commercial and Philina about building over

Philina Lee

$XXX.X XXX% year-over-year, stronger. has quarter, $XXX.X U.S. achieved revenue in In million conviction This the this increase in the million a Kate. AYVAKIT with represents our never $XX.X product in U.S. Thanks, third been ex and million and net brand blockbuster

quarter are launch as in our fundamentals. Our was business AYVAKIT's driven team's to and coming we fruition build strong trajectory proves efforts success. Growth key by our market, this this strength

in AYVAKIT's new steady driven patient by we to discontinuations. and growth therapy strong launch. on patients successful continue Growth in low and is on patients First, AYVAKIT starts see driving

around and to holidays out impact At compliance, our anticipated an this but summer we patient seasonal issue turned than might expected. less dynamics of starts be last call,

QX. the in strong Our team towards a end job great did dynamics, managing these through of resulting demand

and high, on remains We patients remains and duration in therapy, what with expect trends have Compliance consistent growing. strong, patients of continue we've on this a real-world the therapy seen AYVAKIT. to benefit base we demonstrating large of see

goods Second, our mix free remain stable. commercial and of

Our average is has past mid-teens rate goods approval over ISM the free X the and stabilized in since quarters.

this consistent the We to year. remain expect the of remainder for

the a launch we're growth driving quarter, reassessment strong and in results underway complete dynamics of be international the growth Germany. growth. this continued volume. chart which SM among But majority of seeing to how delivered first patient across and with sales volume positive early providers in in AYVAKIT beyond what next third the of accrual indicators Finally, just is and Germany additional year. process, we've prescribing will comprises the prescribing drive Breadth price strong the quarter, seen advanced our IFM shows We lead them In by strong offset both by lower top our German to in several this to the anticipate across XXX we SM ISM launch from and there geographic repeat price geographies leads ISM and planned with experience SM expansion international mirror team launch of This markets. the in depth are in story. U.S. an continue XXXX advanced growth as part

We're growing engaging is across range. with and several adoption broader thousand providers the top this beyond XXX,

[ to As prescribing growth. seeds what see strong new hem/oncs and AYVAKIT in see settings. launch adoption academic we dynamics ] across are and with you'd grows, evenly exactly split continued for experience they community the a want allergists These and plant

specialties of We have prescribing first such by dermatologists. as seen also additional the examples

motivated treatment. can we're example, to where seeing patients dermatologists become For to and diagnose SM more champion, local the move cases

anyone across better to market dynamic streamline activates and the ability who well, the a opportunity root spectrum the how This constellation Awareness among of SM bodes access what a to symptoms. to of market AYVAKIT. further We to yet drives providers treat touch patients understand that proving therapy specialists What than cause of targets start ISM therapy. else. to it broadening urgency and grow with capture to disease our another the FM of to grow continues

let's some Now of our dive initiatives. latest provider and into patient

Our the launched team we X-year of with controlled presented safety to new highlight the Immunology Academy recently Conference. Allergy providers notion resources well and that and efficacy campaign challenge branded at a European along designed Clinical of for the data

and how AYVAKIT, valuable our and can patient on progress the Having data launched AYVAKIT to on initiatives. disease. base experience we targets the hemoncs of campaign share allergists the [ recently more to this. spotlight These further ] educating made are and a direct-to-patient growing awareness Avocet now raise Christy will expand providers source We and provider among considering

We We starting a and our support to catalyst as also find for helpful patients it mentor new expanded for face-to-face is an educated launched treatment. programs. other AYVAKIT, patients patient increased and consider they that patient program, from a master a know hear patient events patient

I'll the enhancing with SM generation we every into patients AYVAKIT community more efforts are expanding and it we to XXXX. potential. share about turn to is drive Our data over continually as near-term now helping head more towards as catalysts are and peak our efforts working. and its initiatives we this launch Christy our quarter,

Christina Rossi

Thanks, Philina.

that body showed been as the care AYVAKIT, significant a extension we've to across PIONEER XXXX. from this to of disease. data a HCPs recently, the amassing and years, SM, safety with demonstrating some chronic of overall We've have AYVAKIT open-label of long-term We this last Most survival spent profile. an safety with and X-plus on durable follow-up treating we And as AYVAKIT with and have and the know data updated of therapies. motivating able continued presented X efficacy in since lifelong years median In that treated of the study. a we of improved on been ISM, patients demonstrate impact X setting data trials versus years, longer-term in patients In clinical evidence find more a the than patients long significantly prior favorable spectrum Advanced standard SM of impact meaningful and disease. publish the follow-up long-term clinical

once not the patients. on mountain flexibility needs of to consistent with of is milligrams AYVAKIT. amass have were individual a that just apart, patients blueprint What treatment to escalated data subset customize reinforcing for their that daily, the the evidence however, continue of who Safety XX HCPs dose we based to

a of care the a treating Our at tremendous and with command patients day. broad table every market being group diagnosing team of providers the has by SM developed health

from unparalleled needs and the an through affords research and knowledge us continuum, patient to depth of understanding the expertise long evolved which development commercialization, have of term. provider an over We across

wild-type portfolio. meeting sparking cycle cycle deliver oral guiding drive enabling I disorders just next-generation potent, same DXXXV and It And Boston, and evolve our of allergists tunable American KIT a mast Asthma saw AYVAKIT KIT value impact in creates And insight how and a weekend virtuous scientific and we're This us from more inhibitor, that was cell selective driving inspired virtuous with exchange and and elenestinib on to mall feedback fuels last where firsthand BLU-XXX. our in Allergy, to us ideas proposition to innovation, across College resulting evidence broadly. of at new us and in Insight the establishing with pursue progress the Immunology inhibitor. strategy

on, profile, early potential safety disease some help on the HARBOR initiate been properties, the ahead touch think look is next which and sharing a BLU-XXX has of approach anticipate team data of the we we we to that for year, this near-term study and and end been of about discussed milestones what the Avocet, XXXX, registration-enabling this of will remain It volunteers. I responses our study healthy the early successful where year our launch global primary truly X advancement focused As inform like on on to by This I'd and to biomarker catalysts including Phase data which includes year-end We elenestinib, exceptional the priority how the an through portfolio. today. track to starting also Part Helena of moving includes with strategic initial BLU-XXX, broad advancing in impact. mast of drug-like cell commercial has

development attempts I of more our second science where mast for the plan hope plans to series And about XX. to dial in November we in focused talk our have cell strategic for on therapy seminars franchise. the you

been cycle our CDKX. Regarding shared emerging including targeting validate closely portfolio, sets, continue we to ESMO promise at the that the data cell of have those tracking

the combination originally I program of We we also And dose advanced particularly Phase the expected. have our study. we our of portion degrader, more are quickly in nearing than escalation the BELA next-generation end parallel, CDKX

the not own move been required cancer our we've capabilities and clear later into forward that stage beyond of we Given have the in development on space BLU-XXX strategic to and will been breast investment engaging significant partnership move discussions. trials,

our sustainable XXXX, profiles optimal strong sharing we evaluating may potential to the and and approach for anticipate highest in of assets and laying about conversations, We team early In revenue like. as determine our to emerging therefore, top exceptional a a plans foundation what growth prioritize with partnership these priorities growth. corporate more line and year. our data both executed has Through investments the value the inhibitors the our best-in-class from are structure timing be look next-generation financial next drive CDKX of programs, would as well our

Mike to now will turn financial results. to over discuss our it I

Michael Landsittel

product few results mentioned press earlier, in continued we outside on the revenue guidance to in XXXX. release. detailed sales based This is favorability now total from call, were Earlier growth revenues to in touch as therapy, product this today's quarter. continued I'll from $XXX guidance the And net product in financial revenue total net $XXX AYVAKIT stronger-than-expected million other compliance morning, for and quarter, Thanks, our third on million expect U.S. we and $XXX.X patients reported Christy. achieve of raising and and are million in highlights performance a factors of on our the AYVAKIT, In updated

by break remained margin year. end stable the to international mid-XXs this in even gross to is Our and of our business track on the net

the expenses R&D flat relatively relatively will operating close this We and third SG&A remained we for of quarter. both expenses year. costs total consistent and remain out at the anticipate remainder million that $XXX.X Our as our

where other opportunity pipeline and As the capital This areas perspective growth long-term with our commercialization ensure strategy early plan the our priorities we're cell is disease to our of squarely drive to remain cell to clear year. is SM on our mast capturing that that more ahead mass next allocation on represents We in market we look therapies share AYVAKIT to conviction portfolio. of our allocation biology the advancing capital XXXX clear. around in XXXX, investment focused

to at hand of quarter. XXXX, reinforcing end the million We our this with path expect we've XXXX. continue cash in $XXX.X on significantly financial position continue cash drop And burn importantly, And the to financial to seen we in strengthen our trend our sustainability. in clear

the value. to of shareholder success disciplined continue to great growth, ongoing long-term launch in to a and we the drive our investment With are AYVAKIT commitment position create to

to back that, operator I'll With over Operator. questions. the call the now turn for

Operator

[Operator Instructions] roster.

first goes Our to TD Cowen. question Marc Frahm of

Marc Frahm

ISM strong side just Maybe on the another quarter. on Congrats to start.

meaningful then getting any or factor the XX seeing into of launch as starting discontinuation reauthorization KIT a you're you're type maybe the kind Just at of should trajectory? X, in of out to Any we of now. wild-type type patients And to we expect number months headwinds inhibition year, terms of a criteria hit kind Or those And pulsatile data maintenance next thresholds need target of think induce kind are a think response? engagement to you of, the you where of the or might do curious, chronically? you do just of really induction to best kind of more levels be approach. get

Kathryn Haviland

Marc. Thanks,

in for So what you I'll seeing maybe authorizations over then and more what of Philina, can it we're a about there. you and for and BLU-XXX patients we're expecting to talk Fouad, terms hand

Philina Lee

to a we of Marc, we patient base patients are as mentioned, seeing you therapy, this grow. expect and significant and on to continue growing

reauthorizations, of of think are strength incredibly terms In I we pleased with that overall, the continues. access

coverage. payer maintained We and have strong secured

have We problems seen not reauthorization. with

In of that discontinuation remains terms low. very the rates,

to growing retain that patient this things I drive on know, to the launch you that our as patients well strong as base continue ability therapy. two as And think is

to connect pleased potential long-term to see of therapy, in chronic for the really really the we're duration So treatment. trends which

Fouad Namouni

question for kit. you thank Marc, wild-type the And on

we a know [ target. type well is ] As I've biologics very a all there. from lot kit of now, good seen work validated

a give this cell with of to to a degranulation navigate the oral the having molecule I and are us like to of this titrate cell. we all depletion and inhibition think activity of XXX think the small development the way and the diseases and of optimal to really type the work give molecules. we happy really of mast And flexibility, I mast monocline molecule us such flexibility us the tune the the schedule allow and developing like between variety

Operator

question Canino next to Stifel. Brad The of goes

Bradley Canino

the terms consider actually in most growth of this I implied in guide to be aggressive you've quarters. provided forward

us coming Can next I've think have gotten what year? imagine the some feedback too guides as XXXX is forecasting and bit appeared think you I the you've incorporate abilities that to up conservative. variables changed, well how as a help guidance I your about views for investors, particularly of and from how previous you understand heard

Kathryn Haviland

you. to we've to really in the can next a as we've tightened you at about to raise about know revenue as Yes, I this where the And last Brad, which year guide I could also we're thank well year we've now this the that point to a million the we're million. more talk and be year, $XXX nearing $XXX which you guidance, But we year . incredibly to about we be. how range at do $XX point to BT going want talked in you as year tremendous million think this pleased be say mean is said, place

Christina Rossi

Yes. Thanks Brad. for the question,

before, its an And therapies, disease-modifying opportunity, switch fighting compelling, such throughout and range what off estimates provide on may for have our on a how for that So look has year the the revenue share of building the entirely privilege is are opportunity, that many our into think the -- first which think has for first to in patients try range we a then an variables So look we what do and new exist outcomes which the right? trying markets, of of but and could philosophy market and revenue, we that at we been not the category imply variables market time. influence And you're challenges. are therapy market an launch like? incredible best that a market, building context is that to of really in did those

have we where and the fall into we're I variables in certainly, be We're definitely now view, bit XX first little we can year done that a months how our year. place a the the year. own in these think frankly, We've are forecasting might of through thrilled context best, sales exceeded of And that our difficult.

we so on providing essentially are a And guide QX.

than land Our a we at whole quarter forecast X when how we're ability year. is much tighter looking to will obviously

so next will guidance year, year into clearly, represents as a it's this than end we really simple for really a we And guidance go launch. thinking year as well be that as the how we our more on will than -- year. the best And now more into

So a will we new in have variables think of We're still, of well. course, know new that this a forecasting therapy market market, the I but sense of impact. good key some quite

you know, some guidance, the typically drug will call, But same. really example, the with IRA as we We to our year philosophy stay changes like, of will be for free aspects in experience us set next think on early having helpful QX informative context that as about guidance. setting and the

Operator

The Benjamin at next to of question Citizen goes Ren JPM.

Reni Benjamin

not? Congratulations bit you potentially a Can ad SG&A? program? what this working a patient to whether share? little great or market are have fingertips direct-to-patient if And quarter. impact the your does do about it is How the at options on grow mentor it working, isn't evaluate the and And you other it new if talk campaign you how that

Kathryn Haviland

the for Ren, question. Thanks,

to the Philina But how Philina, these relative foremost, on think a I direct place educate types where and SG&A sense down in we kind forward activate to us have talked spend patients. now this of critical wonderful initiatives and think we're you some a and little for about of think -- look to efforts patient first these to campaigns pushing as impact that such makes of launch, of at about kind we and and where want do of you I and be doubling of mass, lot talk to a it about. bit that

Philina Lee

growth our We've enterprise think at about -- in off, Yes. are really the across priorities top how our cell just investment for mast starting Ren, I our maybe Blueprint's first level. and launch, And AYVAKIT opportunities elenestinib see certainly invest impactful to continue the find to terms to look return will including we talked on where of in the investment. most we portfolio, XXX. benefit

been guidance that firmly revenue has course on we this launch, to to our how of achieve the never $X.X strong. the are well that that AYVAKIT just peak with terms in seen deliver path in so billion And conviction on you've nearly updated into the translates

further be patients. is growing see the patients we secured that us well-controlled to activate to that's what of Why and possible time activated starting therapy. have to base that initiatives in we direct-to-patient lean we in and into terms for continues engage opportunity the of these be continue that Now have a is in and open now further prescriber an leaning that challenging is critically notion on aperture to to important disease-modifying important to may grow

to that normal of acclimated and new what compelling from normal what and the there's can on nothing behaviors While how transformative to feel disease more sort another like, just their is a patients be may and their have than with activities, patient, of it like or experience like. coping become AYVAKIT their restricting that reclaim the hearing new sense can

And both of launch. will drive so creating to awareness, raising more source the importance going these of terms targeting into initiatives, talking the to critically other be in and of continuing this a in patients about of hear the those from important direct-to-patient disease component of patients opportunities for

Operator

The of next goes Michael Guggenheim. question to Schmidt

Paul Jeng

This is on Michael. for Paul

year to antibodies. way biomarkers compared see. what's the endpoints And like activity quick performance do you balance early then the your that on less sort second in seasonality about Just kit one your Or third of by of to the activity is carry like score. of signals quarter. to classic what's than [indiscernible] clinically on just the the in did by the for play between counterbalanced months right it might the now general oral end? on correlation How agent shown in my over full just a on cell And think the would some expected. about anticipated to Was thinking and simply mast out relevant and markers you've we It efforts the that on the of AYVAKIT actively summer market. be reduction think those seasonality X.X XX BLU-XXX years ISM great had been one

Kathryn Haviland

lot Thanks, Yes. a that. Paul. in There's

is making we'll hand before thing new it that One could as is you launched commentary on then to would to continue disease, therapy. even expect there'll and steady we we believe strong So around there growth the basis. of about type just longer But this week-by-week we starts rare the is variability I on and have we to lumpiness first be in we patient patient over piece think that be take and maybe perspective, been since the a in Fouad. say line, if a

And I last we allayed the that it's as is described. if made and think patients And not has those exactly about been the of commentary have quarter on we what when. things -- was start, it about really clear both is out

Philina, talk about you So more would like to that.

Philina Lee

Yes.

of from that Kate really saw go from up holidays to the But the our out that is think increase in back quarter through strong We've We some importantly, to team that visit. the half to has of the impact done particular most I the lasering we well. quarter And think So an through to sort incredible it these year. can updated teed dynamics quarter. potential see to demand trajectory. can of really guidance. we know year-over-year the have the quarterly a timing job starts I that With managing next impact the quarter alluded patient short-term third of is a the What dynamics. of

firmly think again, places than path greater that XXX% to a path growth us deliver on that are And the I towards of marching We $X year-over-year. billion peak. on over

Kathryn Haviland

about little bit correlation a prescriptive? we're and and And a what to thinking then talk Fouad, from about biomarker [indiscernible] do want you

Fouad Namouni

for the question. Paul, you, Thank

on cell that I said number answering type with the or small with of Marc's the earlier as this developing diseases. really dose can mass mice, molecule, wide are inflammatory range and of the a a the we the We schedule two really tune small to of question navigate target activity the idea

Christy at [indiscernible] pharmacology, we in the We to mentioned, XXXX, look expect subject, the early safety. and data from we pharmacology at our overall As biomarkers, to the and the report look really and we anticipate study titration allowing us number good report including be and I to earlier, a a level will we talked of do of [indiscernible]. about very that the tunability the one early

of More your for a mother. to disease supportive question, varies marker the specifically activity and pharmacodynamic Tryptase is [ from agents one ] the

see tryptase like healthy would So to in volunteers. these

more in in complex like a environment. POC much a We know much is Tryptase of a urticaria, where that some chronic the diseases story, also is but part there more complex already

but example, when more X tryptase, markets. looking you can are look to go you at an As other than type diseases complex just at asthma

opportunity the to have tryptase tryptase. with and share on data we So NBE

Kathryn Haviland

where I'll is mast coming our talk cell. more November seminar a where how XX, in of maybe XXX about we'll again this put And overall in just strategy development in plug thinking kind out we're our for about

you So please can. do tune in, if

Operator

goes The Goldman to next question of Salveen Richter Sachs.

Tommie Reerink

This is on for quarter. Tommie on Salveen. the And congrats

you to view or So from differentiation data some questions previous of that the out MRGP volunteer to on ISM just think here play parts the your aware that do from moving one on starts with derisking some And to follow be maybe two? as you the U.S. up look ex healthy XXXX, strategies regard a as role. here, then of should will especially lay such larger what's we a on be how the overall, to navigating therapeutic And window.

Kathryn Haviland

Yes. maybe XXX. Fouad level be talking Thank question. the And that. will yes. more about of on on a And you you But much QX high the talk about give for we'll very can call, course, just but

Fouad Namouni

fine-tune of in diseases. to to So our the and target a strategy really wild-type to mass development is variety cell from perspective, an go

from patients in will XXX. to anticipate for good showing biologics if and share point one think and expect very concept we a to a therefore, strong to did terms I derisking for for of in your also used. us kit, chronic In of articles a early and job major XXXX continuous to be drug profile we at data type And the the good what that proof POC, today hope look we really in question, be inflection benefit called

is therapeutic of lot a different to the index molecule a that completely fine-tune [indiscernible], overall pharmacology chronic but type having of at achieve from seminar us help Now therapies. improve weeks. diseases with can only biologics on these there diseases. about Kate room a as we a for in we mentioned such small believe in will And we few our talk will these of variety a not in earlier, goal, And

on need as that targets believe, and the We different more max math There number your question Regarding targets does of such a target the community is cell too, on are specifically, and [indiscernible]. cell. scientific this a restricted organ data it's skin. it's to if -- the I clinical And can could analogy. data potentially we -- more when use mean data a because zone, see probably I free really to

we going that cell kit, to the our the or mast is, the On will wild-type or by either wherever the we in skin. the target know in long -- strategy gut in it

And so all after a than type we inhibition kit the is much going targets. strategy believe broader other of

Kathryn Haviland

want lot then, do mentioned. this all little level, And high we Obviously, about what to Chris, about we'll on on think a spend 'XX. more with talk a bit Yes. just you time you

Christina Rossi

Yes.

we'll guidance again provide call. the on So QX

what's what I more starting this about very important. macro think therapy and launch what sort patients variables to on a the been is similar new of are thinking and talking we've more level, we'll going on -- therapy becoming driving patients about be those course, and of over it's time at this that be year broadly to keeping

growing move additional that being internationally, be coming markets year reimbursement pricing and through treated progress launches, we very have as and will of you kit we AYVAKIT into course, on have and that we through substantial a patients launches. We'll from negotiate as base. then, of next number now As we mentioned, new the with carrying

months the IRA I'm get and But factors. the amount year first couple a et substantial innings a and how Every sort we that the year we a year see has early into next view room cetera, into of again, of the year. we'll we that own sure free continued to bit impact, with its about play look out. picture, launch growth of next of are forward is more talk big in as of on drug, for go driving as

Operator

Wells goes Fargo. next The of question to Derek Archila

Derek Archila

and updates Congrats on the here the quarter. on

Just and one just clarifying then one question.

expectation XXX, than might call, line And guess, then factor how second what I exciting. have the I impact and about just in is profile and Or look of some that on the your to kind you and a think guess patient the on just on done. how seasonal you qualitative just of the the been then will kind terms can look reduction guess all Q-over-Q? that in talking antibodies tryptase information you relative give of guys the overall very do of adds, XQ. XQ So does safety with just it antibody? quarter, better like in us on and And here, terms lot the net I magnitude

Kathryn Haviland

Thanks, question. for Yes. the Derek,

around what that, moved qualitative the touched Philina, we do provide of reiterate as how kind how last on to from seasonality on of estimated we end know therapy about can commentary but number away -- about the at there. kind year, projected but I about and of So thinking that you talking seasonality. certainly quarter the we've want we're seen we've you're And of thinking kind Derek,

Philina Lee

Yes.

factors continued significant overall to we're in is on continue peak that to always focused we the trajectory the with going disease as potential. the steady. like months for arc and But of strong basis, what starting that this by this articulated, reiterate We is going grow growth of that we're to that number be patients to just just QX, that in would This I are therapy, Christy fewer showing piece month-to-month holidays. expectation I days. growth patients we launch might and on in really based therapy. business Quarters expect steady is in There know example, growth back said. a most there strong on maybe have and such towards important one. importantly, what to headroom than on think think be that's significant variations I year-to-year steady marching rare launch, most that more a driving continue the And on are

Kathryn Haviland

of of Derek, we're think, coming of our the year I now first kind like And full that end launch.

towards and And come about that's as are And very little and in I year talk shown from of the then, BLU-XXX I is of relative and So able work our faces, some that a body. and specific any to the be unique a Fouad, the and diseases team like move are remarks, do you think through now constructed those out to said the rare my our product, bit do to to to want to given how prepared seen have seeing that about in you're by We everyone understand that our lot what is here we've to a see dynamics data quarter. will we focus around demonstrated that focus. those those right? $X year, confidence SM. that goal are, those plus is The way. that in that have billion we're dynamics continue dynamics And we and that going to from

Fouad Namouni

Yes.

do specifically these when we other on also full need very and to which thing active set spontaneous us will the think Medicine. with I ] anticipate chronic having which the area two believe next achieve of the in will early toxicity met makes all and find important cell we ], major a differentiated myeloid way hand, the cell and opportunity data Developing data and and articaria degranulation earlier, depleting the have to report the is disease, validates to that and approach our for good and extremely need to. hand, the don't this inflection mast a and deep molecule very the very is goals. navigate on on year, and subsets getting Blueprint depletion to [ to clearly, events inhibiting in and by, is urticaria, do for us our mass to good the really biologics. a the far antibody strategy patients conduced to gives we that [ allow the from this with of from the one to reaching point small generate small molecule that is targeting target a -- really without index mentioned arteceria a allow adverse progenitor titrate that. activity difficult us We not therapeutic to and of It

Operator

The Stanley. next question goes to Mike Ulz Morgan of

Michael Ulz

you better get into quarter how sort as just the sort to trends color you strength could on Congrats evolve and being of of on next well. some expect expected. provide we year. highlighted Maybe Maybe and as those than you there more OUS AYVAKIT,

Kathryn Haviland

how has job Yes. want Thanks, beyond done of Mike. We're terms if just international well kind delivering to launch more know incredibly in little team that you talk bit expectations. the been of don't international. about a with The a And tremendous pleased has going. Christy, I

Christina Rossi

really, with strength the We Yes. quarter. the really pleased of were

gate Germany, to of first on see, dynamics of including ethylene and that the course, where the U.S. has centers about seen is in similar gratifying coming which talk ISM we've uptake, a out which academic community. both prescribing and Of from really very we the terms the lot to look in been

was we the quarter, some So of we very to. really the had saw similar that of overcoming dynamics. in headwinds the what uptake referred And strength price that

still we're year, through negotiations lands see. is process in but growth great has and Germany early next more which course, that, Of working that demand to been the have stuff than we'll where the with really offsetting

still which in then, markets, And continue of other [indiscernible]. in see are launching growth course, to we

of negotiations. into get major year, we as pricing next the to see work we ISM start in through As online to expect come more Europe markets we

So top important international an being that of continue. growth. expect about line revenue to I driver we've talked

share when in about opportunity. about U.S. as And U.S. expect outside the would we of potential more the more international well see lion's the become the certainly, as excited opportunity represent of in U.S. course, we Of we the and think the short a but the to we're part both the will peak, continue term, to the important

Kathryn Haviland

international And going thing even. of he to Mike's to the is add one then at end in break mentioned actually commentary, this year, our organization that

top a efficient And and so very financially kind really is in team driving this of growth tremendous line disciplined way.

for be. great to a that's think I -- is us place that So

Operator

Ami The my Needham. to of question next Fadia

Ami Fadia

the on nice Two an firstly Congrats quick elenestinib. quarter. questions, on

Part the year, BLU-XXX, from a I And With the and it about study sort regards in you by initiated AYVAKIT, think of small with development can differentiated do of talk from quite the about how of Q&A. end the strategy being the strategy, see your you've talked tunability X a differs molecule how the HARBOR of of AYVAKIT. to that you bit

would how escalation information parts we dual maybe different you that apply As then a some it data diseases some the where volunteer would initial study And study, take see are could you're into indications of that the there about about thinking you helpful. the of what think from and sort taking it? the be

Kathryn Haviland

about more think maybe answer and question And start Fouad talk -- Ami. elenestinib you, Christy BLU-XXX. Floyd I bit we'll I'll Thank can little about -- Yes. hand a the will

the how little really across a to incredible AYVAKIT advanced want then and for for thinking Do opportunity is to of we're forward innovation unique stepping that and the the is SM I durable with a and you a maximize the position elenestinib And elenestinib longer-term standard we that? position. Blueprint about just in we're think to bring X performance across franchise back one now just at to bringing do the Medicines bit, really have moment care leader Christy, becoming talk about ISM.

Christina Rossi

Yes.

is a headroom of Blueprint we grow. to in is elenestinib to get really decade said, growing and as opportunity strategy amount into, continue This franchise really important, for think next incredibly significant as both to have the beyond. into are patients for with that So our an Kate and think we a that we we SM and is we

expectation is differentiated will that the decade. is the part into will and therapy long a be durable clinical term continue be bring to delivers we that Our latter years AYVAKIT drive next impact the growing the growth franchise elenestinib so to market the and to be can quite of able over to additional the for leader that of really for come. some time value in

what about We'll know But the study looks get by obviously will years X this the of that full is franchise did to we than like more Harbor. be about the understand about a and the you more only that that of we of initiating now of that value part clinical design differentiation. share extend And ago. like. manifestations the XX or delivering so disease we X We way more much

the started targeted we And the study. so than now think and impact PIONEER therapy measure different our in I when it was do space really clinical what to is can ability demonstrates a

actual the on scheduled strategy of mast like. say cell we're HARBOR We'll planning open would in development webinar our as I XX, everybody November design more where more look to And So point our study. about of again, will our that. have about across we terms portfolio. sharing what the cell obviously have to on that mast we

Fouad Namouni

you, Thank question. for Ami, the

doses marker. question time, So know, all from data and are with a looking a I study, XXX. us how variety of and also study of a we as said profile are number pharmacodynamic we we exploring the at understand of cohorts your tunability first say, over help is the would the [indiscernible] patients of

of tunable doses pharmacology So the at on when we of volunteers of variety understanding different in totality for how data and good schedules can and the look healthy inhibition a really develop variety level the the of a us and of of a a at marker impact we pharmacodynamic will titrable dies. can give their

range and mentioned in really we're go about will of number similar for we derisking think really For on X type the and the to, weeks disease the a see really now, them. the indication these a towards a we registrational what as We'll of can is a few development. across some think from what diseases have activity I was on to studies in the how do question second about opportunity variety diseases early think of information. talk about your through way. terms cohort broad past, a of will a and start type and away number targeting and inflammation But part in you of breadth X the broad of wide targeting or How I other in to major of is we it diseases selection step-by-step

Operator

goes Oppenheimer. Scheider The of question to Marcus next

Unknown Analyst

Matt. for on Marcus is This

fair -- this shown already to will it nice that be your say focus asthma. some Is this is You've on of one data preclinical area?

Fouad Namouni

one we'll to type range more of diseases, the at type key of in great X a is as the ask these precisely Obviously, That's question. a be looking obviously. --

many is I in a think thinking. matter diseases more able specific mean really diseases. part of a weeks, bit we'll will in the a I our But say range to inflammation that area it the of of get a be little or safe be in to about few type

Operator

goes of Barclays. Lawson to question next The Peter

Peter Lawson

update. Great. On Really breadth appreciate and Thanks the our it. depth. data X, Slide around for

I dynamic was greater to thought patients. of with XX an than it number interesting Just physicians

an there's could kind if through angle. how of that or to kind there's sensors these beyond if Just grow that talk if you if is grow there room is ability how it of greater patients -- are if this to wondering out plateaus than and

Kathryn Haviland

is seeing talk depth bit quite about as dynamics [indiscernible] as graph you Yes. snapshot will some you providers. just have of drive across And a strength as we've the a that the Thank believe to Philina, Peter. as want for our But well. of saying to continue the know of just we kind that launch. breadth depth opportunity, I that here and And in been the we're question, tremendous the been this of launch, a

Philina Lee

to Yes. and I that Peter, to both grow across see market measures line patients. this in is headroom we metrics your providers significant and the all across bottom question, think

again, the within even in to look substantial treat XXX. are to XXX really top to So those patients, at base, of uptick number providers, on see that we're headroom provider treating if our more XX patients those or we top providers who within and more excited the therapy so continue grow

-- additional as top well across call, to As growing many on picture. we I as are as tiny XXX continue depth. that said providers of breadth part the where that's the see well just a There additional

are haven't on patients really of yet explored such their treating the based of symptomology. constellation we who potential And others broader the as and of dermatology specialties even additional

headroom significant more $X places that on and bottom So a grow, us we're than billion past peak. achieve confident line, really to to

Operator

Prendergast goes next to The question James. Raymond Laura of

Laura Prendergast

or margin gross XX% a know remain generally me. for Any And seeing about for on month-to-month how But you free dynamics you Congrats great you quarter-to-quarter second on do are dynamics? a question average. think or variability then said to just quarter. said any on drug these in expect below expect to quick you guidance I as steady mid-teens you moving forward?

Kathryn Haviland

Yes.

questions. And free drug out And XXXX. talk for you in Laura, we're mentioned, resets to close we you, Philina, about course, year. is do thinking as about thank of this Christy those this want So how as do we're close to the think of going we But rest the attention to to this rest Philina,how want it as you to that painting impact be of the the at of about year? in look for all IRA. January

Philina Lee

Laura. Yes,

the consistent remain launch of So that of of That the free over we've and expect been end year. past patients we the couple mid-teens. quarters, this through talked has the to has how about today drug reached proportion consistent on relatively

base think Part year to in in I this factors on As free And that we a small our eye want the impacts this Kate therapy at resets the patient substantial to from alluded point, changes one changes have like on really, is such IR. next sort thing keep on due drug have these can we'll revenue. to, D of

the think So variables another alluded all to, piece other to look XXXX. along with at, how that influence that will we about

Kathryn Haviland

you to Mike, bit gross do margin little that And the a question asked want about talk Laura

Michael Landsittel

Laura. Thanks, Yes.

with margin, respect of like solid to AYVAKIT. with think like, first all, we position we gross in a Just are

We sold. of have relatively low goods cost

to through. coming And partners remain of high be We enough that see volume this so gross product do have and to stable like really margins in to we at our point the relatively some due launch CStone. expect variation we sales

and be fundamentally, or month see might But we some margins stable you a quarter-to-quarter, so variability. strong. to expect So

Operator

Citi. question next of David Lebowitz The goes to

David Lebowitz

have I you. for two

mix. physician on In academic you've First, versus the broken the community past, down doctors.

on just I unless I wanted studied It's on number and way. elenestinib to update the And it's HARBOR about update then us getting in ask ISM, being could under If two, that just trial. it. missed that I you X know

smoldering So competitive be ISM just to mastocytosis, I'm but curious DSM only why therapy patients. and including to as in IFM out opposed it would as also there studying in

Kathryn Haviland

you more the inclusion how talk a about of just maybe And and about and of criteria the talk bit Philina little mix let we're to elenestinib physicians kind I'll Fouad could Yes. about then thinking there.

Philina Lee

that continues the specialties and for settings. grow So prescriber one sort most AYVAKIT. We is indicators leading see important of to the all of across base, which

continues the between setting. split academic be evenly to mix of terms in and the pretty community So

addressable to first treatment. and broadening well We for lens they really immunologists hemoncs trying continue have And on going for the time. they to evict as the that prescribe first additional as see that repeat importantly, And positive allergists to the as as patients see the more experience on and encouraged growing and we specialties example well. we're continued this see market for as growth move patients and to from potential there interactions of a an dermatology, interest broader in receptivity really see range grow alluded and really treatment. to We towards

Fouad Namouni

your And the registrational pivotal David, to X, question on study. of part our design hardware

last years, many but next all a on of years. all good really only way understanding patients the a disease, indolent -- we the subtypes from advance SM the be mentioned the exploring overall physicians this spectrum the subtypes of this of not looking community as and and will we have in disease, from what many patients for the really Christy working As to disease with this of and been earlier, over have

this and our all knowledge in data these factored is think I development.

of are group our the are the influencing definitions of is able data. the very clearly patients this interesting the we well, very, these we way know patients studies be disease we community. about We'll execute, in to very data smoldering the the of difficult and dedicated of small changes are expert X% on next but specific your to more X.X% that these share or know, work to for weeks that as and group question, months and of it a SM all patients very including with very

Operator

goes time next The the Loganathan question top one before have for of Sudan question We of the to hour. Stephens.

Sudan Loganathan

Congrats my quarter and questions. the taking great on

that focus allocation interested pipeline that in-house elenestinib you areas have the you're established. assets conical late-stage BLU-XXX with in the launch can With have from trajectory strong business a development AYVAKIT you Or other the know-how to maybe you AYVAKIT that bolt-on is established? some M&A and in? developing or activities the with synergies and other the market you've benefit you're have kind Do any the for that that of market interest and into that

Kathryn Haviland

have for research and of been benefit to interest. has a I Yes. has a kind molecules the think tremendous since our able forth innovative just be got you, productivity years And over XX-ish question. against targets Blueprint -- ago, drive growth at to Sudan, team organically. bringing tremendous founding, our our we Thank new the And Medicines of

on prioritizing our and -- to capital we're those programs think really between capital. BLU-XXX our and potential so allocation very internal where AYVAKIT, go focus elenestinib really has how is broad we this And are about

with a in own we don't There's of going about on labs, all lot talk you. our

our is needs. on as on based driving so everybody bring operating able innovation BD efficiency portfolio medical be is from to those programs significant and discuss those. allocate our and dollars We're our that although thinking own patients perspective, to we and and continue to anything and would sense. financial we partner always externally And to optimize that a have forward talking to our that progress, about -- look internally how focus out is there really how own who leverage, But forward both for can to we really, in make

Operator

back Kate Ms. call turn Q&A. to over today's the concludes I That Haviland, you.

Kathryn Haviland

joining Thank Yes. for you, everyone, us today.

most disciplined really has question, and we in off about forward long-term look growth our talking last as on at opportunities we're the just compelling product sustainable short a for us while closing to we come here XXXX talked investment when out we in ramp coupled setting about weeks a into very, value. with to, year. we revenue enhance AYVAKIT's exciting Blueprint very the kick path strong we XXXX, As Medicines, that few put a And drive more up our with shareholder

for you So thank at thank your and all, continued you support Blueprint.

Operator

call. Thank today's conference you. This concludes

disconnect. now may You

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.